The company's third quarter revenue increase was driven in part by strong growth in its molecular biology clinical applications.
Smaller multiplex molecular panels of five or fewer targets will be covered, while a determination of gastrointestinal panel coverage is expected soon.
The firm attributed growth to a diversified geographic footprint and comprehensive offerings based on three key in vitro diagnostics technologies.
The 20-gene assay, which BioMérieux will develop on the BioFire FilmArray platform, distinguishes active TB from latent TB, viral, and bacterial infections.
Sales were driven by a strong flu season and growth in Asia-Pacific business.
Using an immunoassay as an initial screening tool saved approximately $36,000 over multiplex PCR panel use alone when performed in a period of high flu prevalence.
Qiagen believes the flexibility of the Stat-Dx platform for an evolving reimbursement landscape will set it apart from other similar commercial platforms.
Sales of BioFire FilmArray products accounted for more than half of the growth in the quarter.
BioMérieux sees Qvella's system as complementary to its BioFire FilmArray and will consider adopting Qvella's sample treatment technology.
This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.
The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.
Researchers find that people's genetics influence their success at university, but that it is not the only factor.
In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.